Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT03522246IIINewly diagnosed stage III/IV epithelial ovarian cancer that responded to first-line platinum therapyATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)View DrugsArizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT02166905IINY-ESO-1 or LAGE-1+ ovarian cancer with or without residual disease after treatmentA Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 AntigenView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CDX-1401DEC-205/NY-ESO-1 fusion protein CDX-1401Immune response against cancer expressing NY-ESO-1
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO1 to stimulate immune response
NCT03735589I/IINewly diagnosed stage II-IV epithelial ovarian cancer that responded to first-line platinum therapy (inc expansion)A Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Autologous In Vitro-Sensitized CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian CancerView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
Alpha-DC1 vaccineAnti-tumor immune response
Autologous nCTLsAutologous Natural Killer Cell-like nCTLs, autologous natural killer-like cytotoxic lymphocytes, autologous aDC1-induced CTLsAnti-tumor immune response
NCT03054909INewly diagnosed stage III/IV ovarian cancer (maintenance)QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal CancerView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
ALT-803Activates NK cells to stimulate immune response